Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: A prospective cohort study

The Lancet Infectious Diseases

Volumn 16, Issue 4, 2016, Pages 441-448

  Byrne, Elizabeth H ^a   Anahtar, Melis N ^a   Cohen, Kathleen E ^a   Moodley, Amber ^b   Padavattan, Nikita ^c   Ismail, Nasreen ^c   Bowman, Brittany A ^a   Olson, Gregory S ^a   Mabhula, Amanda ^c   Leslie, Alasdair ^c   Ndung'u, Thumbi ^a,c,d   Walker, Bruce D ^a,e   Ghebremichael, Musie S ^a   Dong, Krista L ^b   Kwon, Douglas S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Females Rising through Education   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; FEMALE; FEMALE GENITAL SYSTEM; FOLLICULAR PHASE; HAZARD RATIO; HIV TEST; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUTEAL PHASE; MENSTRUAL CYCLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEXUAL BEHAVIOR; SEXUAL HEALTH; SOUTH AFRICAN; ADOLESCENT; CONTRACEPTION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INCIDENCE; INJECTION; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK; SOUTH AFRICA; YOUNG ADULT;

ADOLESCENT; COHORT STUDIES; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; INJECTIONS; PROGESTINS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SOUTH AFRICA; YOUNG ADULT;

EID: 84951756330     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00429-6     Document Type: Article

References (26)

1. Ross JA, Agwanda AT Increased use of injectable contraception in sub-Saharan Africa. Afr J Reprod Health 2012, 16:68-80.
2. Polis CB, Phillips SJ, Curtis KM, et al. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Contraception 2014, 90:360-390.
3. Ralph LJ, McCoy SI, Shiu K, Padian NS Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis 2015, 15:181-189.
4. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med 2015, 12:e1001778.
5. Noguchi LM, Richardson BA, Baeten JM, et al. Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV 2015, 2:e279-e287.
6. Shelton JD Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis 2012, 12:507-511.
7. Huijbregts RP, Michel KG, Hel Z Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. Contraception 2014, 90:123-129.
8. Africander D, Louw R, Verhoog N, Noeth D, Hapgood JP Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception 2011, 84:423-435.
9. Hughes GC, Thomas S, Li C, Kaja MK, Clark EA Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells. J Immunol 2008, 180:2029-2033.
10. Huijbregts RP, Helton ES, Michel KG, et al. Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology 2013, 154:1282-1295.
11. Mitchell CM, McLemore L, Westerberg K, et al. Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. J Infect Dis 2014, 210:651-655.
12. Sciaranghella G, Wang C, Hu H, et al. CCR5 expression levels in HIV-uninfected women receiving hormonal contraception. J Infect Dis 2015, 212:1397-1401.
13. Anahtar MN, Byrne EH, Doherty KE, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 2015, 42:965-976.
14. Carnathan DG, Wetzel KS, Yu J, et al. Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci USA 2015, 112:518-523.
15. Haase AT Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223.
16. Zhang Z, Schuler T, Zupancic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999, 286:1353-1357.
17. Kleynhans L, Du Plessis N, Allie N, et al. The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis. Infect Immun 2013, 81:1234-1244.
18. Morrison C, Fichorova RN, Mauck C, et al. Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr 2014, 66:109-117.
19. Bradshaw CS, Walker J, Fairley CK, et al. Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women. PLoS One 2013, 8:e57688.
20. Meditz AL, Haas MK, Folkvord JM, et al. HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol 2011, 85:10189-10200.
21. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990, 9:1551-1560.
22. Haase AT Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005, 5:783-792.
23. Crook AM, Ford D, Gafos M, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod 2014, 29:1810-1817.
24. McCoy SI, Zheng W, Montgomery ET, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 2013, 27:1001-1009.
25. Saba E, Origoni M, Taccagni G, et al. Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of the menstrual cycle. Mucosal Immunol 2013, 6:1081-1090.
26. Vishwanathan SA, Guenthner PC, Lin CY, et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011, 57:261-264.